Status: Not yet recruiting
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment. The study includes a Screening Period of up to 4 weeks, a 12-week Treatment Period, and a 4-week Follow-Up Period, for a total participant duration of approximately 20 weeks.
Participants needed: 81
Trial details
Phase: Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: Calixis Inc.Updated: Aug 17, 2026
Eligibility criteria
Males and females 18 through 85 years. [+6]
Chronic urticaria with an identified cause other than chronic spontaneous urtica... [+11]